Tetraphase stock: buy or sell?

TTPH stock price: $0.84 5.00% At close on May 21st, 2019

Updated on:
May 21st, 2019


Tetraphase closed today at $0.84 and rocketed an astounding 5.00%. On May 13th TTPH plunged a dreadful -10.11%.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections.

Should I buy Tetraphase stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading plan that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Tetraphase Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean TTPH will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Tetraphase Pharmaceuticals stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 5 ratings published for TTPH stock in the last 30 days.

The general sentiment of these ratings is bullish for TTPH stock, with 4 positive ratings.
Is TTPH a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-5-10SunTrust Banksn/aBuy
2019-3-15Piper Jaffray Companiesn/aOverweight
2019-3-15Piper Jaffray Companiesn/aOverweight
2019-1-4B. Rileyn/aBuy

Tetraphase stock analysis

Daily outlook

Shares of Tetraphase closed today at $0.84 and rocketed an astounding 5.00%.

Tetraphase shares rocketed 5.00% to $0.84 today. TTPH marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $1.11 would break this short term down trend and open possibilities for reversing this situation.

TTPH stock chart (daily)

Weekly outlook

After sliding a frightening -16.67% in a week last week, Tetraphase closed this week at $0.84 and remained steady a neutral 0.00%.

Tetraphase Pharmaceuticals finally declined under the support line and now is sliding further looking for new supports. Since price and 20-weeks moving average lines crossed down early September, TTPH fell $-2.70 per share (-76.27%).

TTPH stock chart (weekly)

Tetraphase stock price history

Tetraphase stock went public on March 20th, 2013 with a price of $7.201. Since then, TTPH stock lost a -88.30%, with a yearly average of -14.70%.

1: Adjusted price after possible price splits or reverse-splits.

Tetraphase stock historical price chart

TTPH stock reached 52-week highs on June at $4.49, and all-time highs 2015-07-15 with a price of 52.9.

Tetraphase stock price target is $3.80

Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' TTPH stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 4 price forecasts for TTPH stock:
TTPH stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-5-10SunTrust BanksLowers Targetn/a$4.00-
2019-3-15Piper Jaffray CompaniesReiterates$6.00$4.00-33.3%
2019-3-15Piper Jaffray CompaniesLowers Target$6.00$4.00-33.3%
2019-1-4B. RileyInitiatesn/a$3.00-
(in average)$6.00$3.80-37.0%
Moving in a range from $4.00 and $3.00, the price target for TTPH stock is $3.80. In average, analysts' outlook on TTPH price target is negative, downgrading the prediction by a -37.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report on March, Tetraphase plummed a scary -35.38%. Unfortunately, reported EPS is not yet available in our database.
TTPH earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual turnover report draw a super good growth of 95.57% to $18.90 million USD. In line, its income margin (compared to sales) climbed to -381.71%, that is $-72.16 million.

TTPH annual Sales and Income evolution
2013$10 M-$-29.64 M-282.6%-
2014$9.10 M-13.27%$-66.74 M-733.6%125.18%
2015$12 M28.45%$-83.19 M-711.9%24.64%
2016$5.15 M-55.97%$-77.48 M-1505.9%-6.86%
2017$9.67 M87.87%$-114.75 M-1187.2%48.11%
2018$19 M95.57%$-72.16 M-381.7%-37.12%

Quarterly financial results

Tetraphase Pharmaceuticals posted $4.28 M in revenues for 2018-Q4, a 272.20% improvement compared to previous quarter. Reported quarter income marked $-21.48 million with a profit margin of -501.42%. Profit margin boosted a 1,197.79% compared to previous quarter when profit margin was -1,699.22%. When comparing revenues to same quarter last year, Tetraphase sales marked an astounding gain and skyrocketed a 69.46%.
TTPH quarterly Sales and Income evolution
2017-Q1$1 M-$-29.46 M-1977.2%-
2017-Q2$2 M6.71%$-31.81 M-2000.6%7.98%
2017-Q3$4 M155.79%$-30.01 M-737.8%-5.66%
2017-Q4$3 M-37.84%$-23.48 M-928.6%-21.77%
2018-Q1$2 M-25.20%$-21.58 M-1141.0%-8.09%
2018-Q2$12 M512.32%$-9.54 M-82.4%-55.77%
2018-Q3$1 M-90.06%$-19.56 M-1699.2%104.95%
2018-Q4$4 M272.20%$-21.48 M-501.4%9.83%

Tetraphase ownership

When you are planning to buy shares of a stock, it's always worth to overview its ownership structure.

Tetraphase shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.61% of all shares.

In case of Tetraphase stock, 45.24% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for TTPH stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Tetraphase Pharmaceuticals:

Market cap$45.6 M$204.3 B$6.0 M$230.8 B
Total shares54.3 M2,570.0 M17.2 M5,550.0 M
Float shares53.9 M2,570.0 M5.3 M5,520.0 M
  - Institutional holdings (%)45.2%78.3%4.1%76.2%
  - Insider holdings (%)0.6%0.1%25.9%0.0%
Shares in short selling0.0%0.0%0.0%0.0%

Tetraphase summary

Tuesday, May 21st, 2019
Day range$0.75 - $0.89
Previous close$0.80
Session gain5.00%
Average true range$0.08
50d mov avg$1.13
100d mov avg$1.20
200d mov avg$1.82
Daily patternlb06a
Weekly pattern lt01c

Tetraphase performance

To better understand Tetraphase performance you must compare its gains with other related stocks in same sector or industry. For Tetraphase Pharmaceuticals, the benchmark is made against Merck, NovaBay Pharmaceuticals and Pfizer.
TTPHTetraphase Pharma...-30.00%-54.59%-77.48%
NBYNovaBay Pharmaceu...-73.88%-71.07%-86.27%

Tetraphase competitors

We selected a few stocks to conform a list of Tetraphase Pharmaceuticals competitors to check if you are interested in investing in TTPH: